Immuron Limited (IMRN) is a Biotechnology company in the Healthcare sector, currently trading at $0.83. It has a SharesGrow Score of 45/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
Valuation: IMRN trades at a trailing Price-to-Earnings (P/E) of -1.6 (S&P 500 average ~25).
Financials: revenue is $7M, +118.7%/yr average growth. Net income is $5M (loss), growing at -30.4%/yr. Net profit margin is -71.6% (negative). Gross margin is 65.4% (-3 pp trend).
Balance sheet: total debt is $117,127 against $8M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 5.07 (strong liquidity). Debt-to-assets is 1.2%. Total assets: $10M.
Analyst outlook: 1 / 1 analysts rate IMRN as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 41/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).
